Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater
Individuals with adenocarcinoma of the ampulla of Vater demonstrate a broad range of outcomes, presumably because these cancers may arise from any one of the three epithelia that converge at that location. This variability poses challenges for clinical decision making and the development of novel th...
Uložené v:
| Vydané v: | Journal of clinical oncology Ročník 31; číslo 10; s. 1348 |
|---|---|
| Hlavní autori: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | English |
| Vydavateľské údaje: |
United States
01.04.2013
|
| Predmet: | |
| ISSN: | 1527-7755, 1527-7755 |
| On-line prístup: | Zistit podrobnosti o prístupe |
| Tagy: |
Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
|
| Abstract | Individuals with adenocarcinoma of the ampulla of Vater demonstrate a broad range of outcomes, presumably because these cancers may arise from any one of the three epithelia that converge at that location. This variability poses challenges for clinical decision making and the development of novel therapeutic strategies.
We assessed the potential clinical utility of histomolecular phenotypes defined using a combination of histopathology and protein expression (CDX2 and MUC1) in 208 patients from three independent cohorts who underwent surgical resection for adenocarcinoma of the ampulla of Vater.
Histologic subtype and CDX2 and MUC1 expression were significant prognostic variables. Patients with a histomolecular pancreaticobiliary phenotype (CDX2 negative, MUC1 positive) segregated into a poor prognostic group in the training (hazard ratio [HR], 3.34; 95% CI, 1.69 to 6.62; P < .001) and both validation cohorts (HR, 5.65; 95% CI, 2.77 to 11.5; P < .001 and HR, 2.78; 95% CI, 1.25 to 7.17; P = .0119) compared with histomolecular nonpancreaticobiliary carcinomas. Further stratification by lymph node (LN) status defined three clinically relevant subgroups: one, patients with histomolecular nonpancreaticobiliary (intestinal) carcinoma without LN metastases who had an excellent prognosis; two, those with histomolecular pancreaticobiliary carcinoma with LN metastases who had a poor outcome; and three, the remainder of patients (nonpancreaticobiliary, LN positive or pancreaticobiliary, LN negative) who had an intermediate outcome.
Histopathologic and molecular criteria combine to define clinically relevant histomolecular phenotypes of adenocarcinoma of the ampulla of Vater and potentially represent distinct diseases with significant implications for current therapeutic strategies, the ability to interpret past clinical trials, and future trial design. |
|---|---|
| AbstractList | Individuals with adenocarcinoma of the ampulla of Vater demonstrate a broad range of outcomes, presumably because these cancers may arise from any one of the three epithelia that converge at that location. This variability poses challenges for clinical decision making and the development of novel therapeutic strategies.
We assessed the potential clinical utility of histomolecular phenotypes defined using a combination of histopathology and protein expression (CDX2 and MUC1) in 208 patients from three independent cohorts who underwent surgical resection for adenocarcinoma of the ampulla of Vater.
Histologic subtype and CDX2 and MUC1 expression were significant prognostic variables. Patients with a histomolecular pancreaticobiliary phenotype (CDX2 negative, MUC1 positive) segregated into a poor prognostic group in the training (hazard ratio [HR], 3.34; 95% CI, 1.69 to 6.62; P < .001) and both validation cohorts (HR, 5.65; 95% CI, 2.77 to 11.5; P < .001 and HR, 2.78; 95% CI, 1.25 to 7.17; P = .0119) compared with histomolecular nonpancreaticobiliary carcinomas. Further stratification by lymph node (LN) status defined three clinically relevant subgroups: one, patients with histomolecular nonpancreaticobiliary (intestinal) carcinoma without LN metastases who had an excellent prognosis; two, those with histomolecular pancreaticobiliary carcinoma with LN metastases who had a poor outcome; and three, the remainder of patients (nonpancreaticobiliary, LN positive or pancreaticobiliary, LN negative) who had an intermediate outcome.
Histopathologic and molecular criteria combine to define clinically relevant histomolecular phenotypes of adenocarcinoma of the ampulla of Vater and potentially represent distinct diseases with significant implications for current therapeutic strategies, the ability to interpret past clinical trials, and future trial design. Individuals with adenocarcinoma of the ampulla of Vater demonstrate a broad range of outcomes, presumably because these cancers may arise from any one of the three epithelia that converge at that location. This variability poses challenges for clinical decision making and the development of novel therapeutic strategies.PURPOSEIndividuals with adenocarcinoma of the ampulla of Vater demonstrate a broad range of outcomes, presumably because these cancers may arise from any one of the three epithelia that converge at that location. This variability poses challenges for clinical decision making and the development of novel therapeutic strategies.We assessed the potential clinical utility of histomolecular phenotypes defined using a combination of histopathology and protein expression (CDX2 and MUC1) in 208 patients from three independent cohorts who underwent surgical resection for adenocarcinoma of the ampulla of Vater.PATIENTS AND METHODSWe assessed the potential clinical utility of histomolecular phenotypes defined using a combination of histopathology and protein expression (CDX2 and MUC1) in 208 patients from three independent cohorts who underwent surgical resection for adenocarcinoma of the ampulla of Vater.Histologic subtype and CDX2 and MUC1 expression were significant prognostic variables. Patients with a histomolecular pancreaticobiliary phenotype (CDX2 negative, MUC1 positive) segregated into a poor prognostic group in the training (hazard ratio [HR], 3.34; 95% CI, 1.69 to 6.62; P < .001) and both validation cohorts (HR, 5.65; 95% CI, 2.77 to 11.5; P < .001 and HR, 2.78; 95% CI, 1.25 to 7.17; P = .0119) compared with histomolecular nonpancreaticobiliary carcinomas. Further stratification by lymph node (LN) status defined three clinically relevant subgroups: one, patients with histomolecular nonpancreaticobiliary (intestinal) carcinoma without LN metastases who had an excellent prognosis; two, those with histomolecular pancreaticobiliary carcinoma with LN metastases who had a poor outcome; and three, the remainder of patients (nonpancreaticobiliary, LN positive or pancreaticobiliary, LN negative) who had an intermediate outcome.RESULTSHistologic subtype and CDX2 and MUC1 expression were significant prognostic variables. Patients with a histomolecular pancreaticobiliary phenotype (CDX2 negative, MUC1 positive) segregated into a poor prognostic group in the training (hazard ratio [HR], 3.34; 95% CI, 1.69 to 6.62; P < .001) and both validation cohorts (HR, 5.65; 95% CI, 2.77 to 11.5; P < .001 and HR, 2.78; 95% CI, 1.25 to 7.17; P = .0119) compared with histomolecular nonpancreaticobiliary carcinomas. Further stratification by lymph node (LN) status defined three clinically relevant subgroups: one, patients with histomolecular nonpancreaticobiliary (intestinal) carcinoma without LN metastases who had an excellent prognosis; two, those with histomolecular pancreaticobiliary carcinoma with LN metastases who had a poor outcome; and three, the remainder of patients (nonpancreaticobiliary, LN positive or pancreaticobiliary, LN negative) who had an intermediate outcome.Histopathologic and molecular criteria combine to define clinically relevant histomolecular phenotypes of adenocarcinoma of the ampulla of Vater and potentially represent distinct diseases with significant implications for current therapeutic strategies, the ability to interpret past clinical trials, and future trial design.CONCLUSIONHistopathologic and molecular criteria combine to define clinically relevant histomolecular phenotypes of adenocarcinoma of the ampulla of Vater and potentially represent distinct diseases with significant implications for current therapeutic strategies, the ability to interpret past clinical trials, and future trial design. |
| Author | Bersani, Samantha Carter, C Ross Crippa, Stefano Foulis, Alan K Mohamed, Mohamed A A Colvin, Emily K Cowley, Mark J McKay, Colin J Falconi, Massimo Gill, Anthony J Bassi, Claudio Jamieson, Nigel B Scarpa, Aldo Pajic, Marina Chou, Angela Mead, R Scott Chang, David K Pinese, Mark Jones, Marc D Johns, Amber L Scarlett, Christopher J Wu, Jianmin Sperandio, Nicola Oien, Karin A Biankin, Andrew V Samra, Jaswinder S Sutherland, Robert L Humphris, Jeremy L Chin, Venessa T Kench, James G Pinho, Andreia V Toon, Christopher Nagrial, Adnan M Musgrove, Elizabeth A Rooman, Ilse Lawlor, Rita T Corbo, Vincenzo Chantrill, Lorraine A Dickson, Euan J |
| Author_xml | – sequence: 1 givenname: David K surname: Chang fullname: Chang, David K organization: Cancer Research Program, Garvan Institute of Medical Research, Sydney, NSW 2010 Australia – sequence: 2 givenname: Nigel B surname: Jamieson fullname: Jamieson, Nigel B – sequence: 3 givenname: Amber L surname: Johns fullname: Johns, Amber L – sequence: 4 givenname: Christopher J surname: Scarlett fullname: Scarlett, Christopher J – sequence: 5 givenname: Marina surname: Pajic fullname: Pajic, Marina – sequence: 6 givenname: Angela surname: Chou fullname: Chou, Angela – sequence: 7 givenname: Mark surname: Pinese fullname: Pinese, Mark – sequence: 8 givenname: Jeremy L surname: Humphris fullname: Humphris, Jeremy L – sequence: 9 givenname: Marc D surname: Jones fullname: Jones, Marc D – sequence: 10 givenname: Christopher surname: Toon fullname: Toon, Christopher – sequence: 11 givenname: Adnan M surname: Nagrial fullname: Nagrial, Adnan M – sequence: 12 givenname: Lorraine A surname: Chantrill fullname: Chantrill, Lorraine A – sequence: 13 givenname: Venessa T surname: Chin fullname: Chin, Venessa T – sequence: 14 givenname: Andreia V surname: Pinho fullname: Pinho, Andreia V – sequence: 15 givenname: Ilse surname: Rooman fullname: Rooman, Ilse – sequence: 16 givenname: Mark J surname: Cowley fullname: Cowley, Mark J – sequence: 17 givenname: Jianmin surname: Wu fullname: Wu, Jianmin – sequence: 18 givenname: R Scott surname: Mead fullname: Mead, R Scott – sequence: 19 givenname: Emily K surname: Colvin fullname: Colvin, Emily K – sequence: 20 givenname: Jaswinder S surname: Samra fullname: Samra, Jaswinder S – sequence: 21 givenname: Vincenzo surname: Corbo fullname: Corbo, Vincenzo – sequence: 22 givenname: Claudio surname: Bassi fullname: Bassi, Claudio – sequence: 23 givenname: Massimo surname: Falconi fullname: Falconi, Massimo – sequence: 24 givenname: Rita T surname: Lawlor fullname: Lawlor, Rita T – sequence: 25 givenname: Stefano surname: Crippa fullname: Crippa, Stefano – sequence: 26 givenname: Nicola surname: Sperandio fullname: Sperandio, Nicola – sequence: 27 givenname: Samantha surname: Bersani fullname: Bersani, Samantha – sequence: 28 givenname: Euan J surname: Dickson fullname: Dickson, Euan J – sequence: 29 givenname: Mohamed A A surname: Mohamed fullname: Mohamed, Mohamed A A – sequence: 30 givenname: Karin A surname: Oien fullname: Oien, Karin A – sequence: 31 givenname: Alan K surname: Foulis fullname: Foulis, Alan K – sequence: 32 givenname: Elizabeth A surname: Musgrove fullname: Musgrove, Elizabeth A – sequence: 33 givenname: Robert L surname: Sutherland fullname: Sutherland, Robert L – sequence: 34 givenname: James G surname: Kench fullname: Kench, James G – sequence: 35 givenname: C Ross surname: Carter fullname: Carter, C Ross – sequence: 36 givenname: Anthony J surname: Gill fullname: Gill, Anthony J – sequence: 37 givenname: Aldo surname: Scarpa fullname: Scarpa, Aldo – sequence: 38 givenname: Colin J surname: McKay fullname: McKay, Colin J – sequence: 39 givenname: Andrew V surname: Biankin fullname: Biankin, Andrew V |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/23439753$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUEtLxDAYDLLiPvTuSXL00ppnkx5lcV1lYS96Lmnyla00SW1aYf-9i67gaWaYYRhmiWYhBkDolpKcMkIeXtf7nBHKclHkWhf6Ai2oZCpTSsrZPz5Hy5Q-CKFCc3mF5owLXirJF2i_bdMYfezATp0ZcH-AEMdjDwmb4HCcRhs94DZg406ONYNtQ_QGxwaPB8DG91PX_cgvM8JwjS4b0yW4OeMKvW-e3tbbbLd_flk_7jLLCzpmTihpGytFrY22TDtTG2sVAKGcNKYRVJe2JsKUtG4K4YDpUnNXWg2qoLVjK3T_29sP8XOCNFa-TRZOUwLEKVWUM6Y4FYU-Re_O0an24Kp-aL0ZjtXfCewbByVhyg |
| CitedBy_id | crossref_primary_10_3390_cancers15245772 crossref_primary_10_1038_s41416_020_0755_4 crossref_primary_10_1097_JP9_0000000000000032 crossref_primary_10_1016_j_ejso_2022_10_001 crossref_primary_10_1038_s41598_019_49179_w crossref_primary_10_1007_s12253_019_00754_6 crossref_primary_10_1016_j_ejso_2020_04_011 crossref_primary_10_1186_s12885_016_2677_3 crossref_primary_10_1002_jso_25311 crossref_primary_10_5858_arpa_2024_0160_RA crossref_primary_10_4103_IJPM_IJPM_1440_20 crossref_primary_10_1016_j_amsu_2018_04_002 crossref_primary_10_4103_IJPM_IJPM_726_20 crossref_primary_10_1245_s10434_024_15555_8 crossref_primary_10_4251_wjgo_v9_i10_407 crossref_primary_10_5858_arpa_2022_0131_OA crossref_primary_10_1002_cncr_31951 crossref_primary_10_1097_PAS_0000000000000863 crossref_primary_10_1245_s10434_014_4267_4 crossref_primary_10_1007_s00423_022_02563_z crossref_primary_10_1016_j_amjsurg_2021_04_001 crossref_primary_10_14694_EdBook_AM_2014_34_112 crossref_primary_10_1038_s41598_023_42386_6 crossref_primary_10_1016_j_suronc_2022_101841 crossref_primary_10_1016_j_hpb_2019_07_006 crossref_primary_10_1007_s00259_014_2907_3 crossref_primary_10_1016_j_surg_2015_02_001 crossref_primary_10_1007_s12253_019_00584_6 crossref_primary_10_1016_j_ctrv_2013_05_008 crossref_primary_10_1200_JCO_2013_50_9331 crossref_primary_10_1245_s10434_024_16355_w crossref_primary_10_1007_s11864_021_00894_5 crossref_primary_10_1517_14656566_2014_891016 crossref_primary_10_1016_j_humpath_2022_06_009 crossref_primary_10_1097_SLA_0000000000001999 crossref_primary_10_4251_wjgo_v12_i3_347 crossref_primary_10_1016_j_pan_2017_01_007 crossref_primary_10_1177_1066896918784666 crossref_primary_10_1016_j_prp_2018_04_018 crossref_primary_10_23736_S1121_421X_18_02543_6 crossref_primary_10_1186_1471_2407_14_458 crossref_primary_10_1038_s41416_019_0415_8 crossref_primary_10_1245_s10434_017_6098_6 crossref_primary_10_3390_biomedicines11082326 crossref_primary_10_1111_his_13254 crossref_primary_10_1159_000443304 crossref_primary_10_1002_jso_23600 crossref_primary_10_1111_his_12324 crossref_primary_10_1158_1078_0432_CCR_21_1906 crossref_primary_10_1016_j_pan_2021_03_005 crossref_primary_10_4251_wjgo_v10_i11_370 crossref_primary_10_1186_s12957_023_03289_y crossref_primary_10_3748_wjg_v26_i43_6822 crossref_primary_10_1097_MPA_0000000000000385 crossref_primary_10_1136_gutjnl_2024_333368 crossref_primary_10_3390_medicina57111238 crossref_primary_10_1007_s12094_019_02278_6 crossref_primary_10_1016_j_tranon_2022_101414 crossref_primary_10_1097_MPA_0000000000001194 crossref_primary_10_3389_fonc_2021_795891 crossref_primary_10_1002_ueg2_70074 crossref_primary_10_1007_s11605_020_04879_x crossref_primary_10_1016_j_humpath_2013_10_020 crossref_primary_10_3389_fimmu_2024_1433235 crossref_primary_10_1038_bjc_2015_172 crossref_primary_10_3390_cancers16152756 crossref_primary_10_1007_s11605_018_3797_7 crossref_primary_10_1016_j_suc_2016_07_004 crossref_primary_10_1002_cam4_2181 crossref_primary_10_1007_s00428_018_2400_7 crossref_primary_10_1038_s41598_020_79836_4 crossref_primary_10_1016_j_humpath_2023_07_011 crossref_primary_10_1016_j_hpb_2021_03_011 crossref_primary_10_1159_000510961 crossref_primary_10_1002_onco_13821 crossref_primary_10_1080_17474124_2020_1766965 crossref_primary_10_1002_jso_24274 crossref_primary_10_1007_s00595_021_02270_0 crossref_primary_10_1016_j_suronc_2023_101994 crossref_primary_10_1007_s11605_017_3489_8 crossref_primary_10_1080_2162402X_2022_2111906 crossref_primary_10_1038_modpathol_2016_124 crossref_primary_10_1016_j_pan_2015_04_008 crossref_primary_10_1200_JCO_2013_51_3176 crossref_primary_10_1016_j_pan_2019_01_019 crossref_primary_10_1016_j_humpath_2018_08_024 crossref_primary_10_1007_s12029_020_00479_9 crossref_primary_10_4081_oncol_2019_440 crossref_primary_10_5858_arpa_2014_0205_RA crossref_primary_10_1007_s00330_017_5259_0 crossref_primary_10_1097_XCS_0000000000000769 crossref_primary_10_1186_s12885_024_12398_0 crossref_primary_10_3390_ijms22094388 crossref_primary_10_1245_s10434_018_6567_6 crossref_primary_10_1007_s00262_018_02293_6 crossref_primary_10_3810_hp_2014_12_1158 crossref_primary_10_3389_fonc_2024_1407828 crossref_primary_10_3390_cancers15051454 crossref_primary_10_12998_wjcc_v12_i2_267 crossref_primary_10_3390_jcm9113622 crossref_primary_10_1080_08998280_2015_11929185 crossref_primary_10_1097_SLA_0000000000003177 crossref_primary_10_4251_wjgo_v15_i4_677 crossref_primary_10_1016_j_modpat_2023_100181 crossref_primary_10_1016_j_path_2020_05_005 crossref_primary_10_1002_jso_23529 crossref_primary_10_1016_j_asjsur_2020_03_007 crossref_primary_10_1007_s12029_019_00297_8 crossref_primary_10_1016_j_humpath_2017_10_010 crossref_primary_10_1016_j_humpath_2015_05_012 crossref_primary_10_1053_j_semdp_2015_02_014 crossref_primary_10_1136_jclinpath_2019_205912 |
| ContentType | Journal Article |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1200/JCO.2012.46.8868 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology |
| EISSN | 1527-7755 |
| ExternalDocumentID | 23439753 |
| Genre | Research Support, Non-U.S. Gov't Journal Article |
| GrantInformation_xml | – fundername: Chief Scientist Office grantid: CAF/06/24 |
| GroupedDBID | --- .55 0R~ 18M 2WC 34G 39C 4.4 53G 5GY 5RE 8F7 AARDX AAWTL AAYEP ABBLC ABJNI ABOCM ACGFO ACGFS ACGUR ADBBV AEGXH AENEX AIAGR ALMA_UNASSIGNED_HOLDINGS BAWUL C45 CGR CS3 CUY CVF DIK EBS ECM EIF EJD F5P F9R FBNNL FD8 GX1 H13 HZ~ IH2 KQ8 L7B LSO MJL N9A NPM O9- OK1 OVD OWW P2P QTD R1G RHI RLZ RUC SJN TEORI TR2 TWZ UDS VVN WH7 X7M YFH YQY 7X8 |
| ID | FETCH-LOGICAL-c361t-d475cfc54b8a8c28dabacc7ee0130faf4189cb04a91bf64de28983d9c8e761bd2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 133 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000317003300024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1527-7755 |
| IngestDate | Fri Sep 05 10:51:54 EDT 2025 Mon Jul 21 05:30:16 EDT 2025 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 10 |
| Language | English |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c361t-d475cfc54b8a8c28dabacc7ee0130faf4189cb04a91bf64de28983d9c8e761bd2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
| PMID | 23439753 |
| PQID | 1322731468 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_1322731468 pubmed_primary_23439753 |
| PublicationCentury | 2000 |
| PublicationDate | 2013-04-01 |
| PublicationDateYYYYMMDD | 2013-04-01 |
| PublicationDate_xml | – month: 04 year: 2013 text: 2013-04-01 day: 01 |
| PublicationDecade | 2010 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Journal of clinical oncology |
| PublicationTitleAlternate | J Clin Oncol |
| PublicationYear | 2013 |
| References | 24043730 - J Clin Oncol. 2013 Oct 20;31(30):3843-4. doi: 10.1200/JCO.2013.51.3176. 24043729 - J Clin Oncol. 2013 Oct 20;31(30):3842-3. doi: 10.1200/JCO.2013.50.9331. |
| References_xml | – reference: 24043730 - J Clin Oncol. 2013 Oct 20;31(30):3843-4. doi: 10.1200/JCO.2013.51.3176. – reference: 24043729 - J Clin Oncol. 2013 Oct 20;31(30):3842-3. doi: 10.1200/JCO.2013.50.9331. |
| SSID | ssj0014835 |
| Score | 2.4777846 |
| Snippet | Individuals with adenocarcinoma of the ampulla of Vater demonstrate a broad range of outcomes, presumably because these cancers may arise from any one of the... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | 1348 |
| SubjectTerms | Adenocarcinoma - metabolism Adenocarcinoma - pathology Adult Aged Aged, 80 and over Ampulla of Vater - metabolism Ampulla of Vater - pathology CDX2 Transcription Factor Cohort Studies Common Bile Duct Neoplasms - metabolism Common Bile Duct Neoplasms - pathology Female Homeodomain Proteins - biosynthesis Humans Immunohistochemistry Kaplan-Meier Estimate Keratin-20 - biosynthesis Keratin-7 - biosynthesis Male Middle Aged Mucin-1 - biosynthesis Mucin-2 - biosynthesis Multivariate Analysis Neoplasm Staging Prognosis |
| Title | Histomolecular phenotypes and outcome in adenocarcinoma of the ampulla of vater |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/23439753 https://www.proquest.com/docview/1322731468 |
| Volume | 31 |
| WOSCitedRecordID | wos000317003300024&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV3LS8MwGA_qRLz4mK_5IoLsZN2aJml6EhkOEbf1MGG3kVdhh7Vz3Qb77_3SdfQkCF4KPZSE9Jcvv--R74fQY5tEkvHAeJT40qNUMdhzvvAUk7KtQt4mpmji-hn2-2I0iuIy4JaXZZVbm1gYapNpFyNvOa8pDNxFoZfZt-dUo1x2tZTQ2EW1AKiMQ3U4qrIIVBQCm065FVgkY2WaEoDR-ugMXF0XeaYcsMLF7wSzOGi6x_-d4gk6Kikmft1g4hTt2LSODnplEr2OmvGmXfX6CQ-r21f5E27iuGpkvT5Dg6KHyHQroItdOVjmYrY5lqnB2XIB87J4kmIJ1gsOxTkMkE0lzhIMvBLL6Qwc3OJ1BZR2fo6-um_DzrtXCjB4OuD-wjM0ZDrRjCohhSbCSCW1Dq116c5EJtQXkVZtKiNfJZwaC96bCEykhQ25rwy5QHtpltorhBOrqJERI0wZqlUouNSRZVaBRQCPhjfQw3ZNxwBwl7WQqc2W-bha1Qa63PyY8WzTiWNMAsenWHD9h69v0CEppCxc1c0tqiWwve0d2terxSSf3xfIgWc_7v0AJtbOsw |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Histomolecular+phenotypes+and+outcome+in+adenocarcinoma+of+the+ampulla+of+vater&rft.jtitle=Journal+of+clinical+oncology&rft.au=Chang%2C+David+K&rft.au=Jamieson%2C+Nigel+B&rft.au=Johns%2C+Amber+L&rft.au=Scarlett%2C+Christopher+J&rft.date=2013-04-01&rft.eissn=1527-7755&rft.volume=31&rft.issue=10&rft.spage=1348&rft_id=info:doi/10.1200%2FJCO.2012.46.8868&rft_id=info%3Apmid%2F23439753&rft_id=info%3Apmid%2F23439753&rft.externalDocID=23439753 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1527-7755&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1527-7755&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1527-7755&client=summon |